SeekingAlpha · Feb 27, 2026
TG
NASDAQ · TGTX
TG Therapeutics, Inc.
Healthcare · Biotechnology
$53.04
Up+$3.71 (+6.99%)
Updated Sep 16, 2026, 2:11 PM
SID Score
5.5/10
Composite research score
Smart Money
62/100
Neutral
- Market cap
- 5.08B
- P/E ratio
- 77.67
- Dividend yield
- 0.00%
- 52-week range
- $26.76 – $59.30
- Volume
- 1.76M
- Avg. volume
- 1.87M
Price performance
TGTX price history
1M range · 20 trading sessions · Daily adjusted prices
TGTX closed at $53.04 after 20 trading sessions, up 5.53% for the selected period.
- Last close
- $53.04
- Period change
- +5.53%
- Period low
- $50.26
- Period high
- $56.90
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $53.59 | $54.4124 | $52.5001 | $53.04 | 1.76M |
| Sep 14, 2026 | $53.97 | $54.20 | $53.19 | $54.00 | 1.36M |
| Sep 11, 2026 | $55.71 | $56.26 | $53.47 | $53.89 | 1.37M |
| Sep 10, 2026 | $54.36 | $55.41 | $54.01 | $55.39 | 1.37M |
| Sep 9, 2026 | $55.55 | $57.14 | $54.24 | $54.65 | 1.41M |
| Sep 8, 2026 | $55.34 | $55.925 | $54.09 | $55.74 | 1.09M |
| Sep 4, 2026 | $56.30 | $56.70 | $55.56 | $55.985 | 992.97K |
| Sep 3, 2026 | $57.40 | $58.47 | $56.19 | $56.71 | 1.57M |
| Sep 2, 2026 | $56.18 | $57.87 | $54.70 | $56.90 | 2.36M |
| Sep 1, 2026 | $53.00 | $56.27 | $52.11 | $56.09 | 3.2M |
| Aug 31, 2026 | $53.58 | $54.36 | $52.67 | $54.30 | 1.62M |
| Aug 28, 2026 | $55.53 | $55.53 | $53.83 | $53.93 | 1.03M |
| Aug 27, 2026 | $55.00 | $55.97 | $54.15 | $55.72 | 1.22M |
| Aug 26, 2026 | $55.50 | $56.04 | $54.53 | $55.03 | 963.31K |
| Aug 25, 2026 | $56.66 | $57.90 | $54.68 | $55.42 | 1.99M |
| Aug 24, 2026 | $53.19 | $56.49 | $52.00 | $56.01 | 2.85M |
| Aug 21, 2026 | $51.10 | $56.87 | $49.97 | $54.27 | 5.56M |
| Aug 20, 2026 | $51.65 | $53.18 | $50.52 | $50.56 | 2.44M |
| Aug 19, 2026 | $51.62 | $52.335 | $50.71 | $51.69 | 1.29M |
| Aug 18, 2026 | $49.28 | $50.29 | $48.98 | $50.26 | 1.2M |
Latest TGTX news
The latest Smart Investors Daily articles mentioning TGTX.
Stock researchCompany · Overview
TGTX research
Overview
Company profile and research snapshot.
Company profile
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $60.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 1, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 7, 2026 | JP Morgan | Overweight | — |
| Jul 27, 2026 | B. Riley Securities | Buy | — |
| Jul 13, 2026 | HC Wainwright & Co. | Buy | — |
| Jul 7, 2026 | B of A Securities | Underperform | — |
News briefing
No generated briefing is available yet.
ChartMill · Feb 26, 2026
TG THERAPEUTICS INC (NASDAQ:TGTX) Q4 2025 Earnings Miss Estimates Despite Strong BRIUMVI Outlook
TG Therapeutics reported mixed Q4 results with BRIUMVI sales strong but EPS missing estimates. The company raised its 2026 revenue outlook, though shares fell on the earnings news.
SeekingAlpha · Feb 26, 2026
TG Therapeutics, Inc. (TGTX) Q4 2025 Earnings Call Transcript
Benzinga · Feb 26, 2026
TG Therapeutics shares are trading lower after the company reported worse-than-expected Q4 EPS results.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
